Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a large decrease in short interest in the month of December. As of December 31st, there was short interest totaling 160,518 shares, a decrease of 42.5% from the December 15th total of 279,178 shares. Based on an average trading volume of 63,451 shares, the short-interest ratio is currently 2.5 days. Currently, 11.5% of the shares of the company are sold short. Currently, 11.5% of the shares of the company are sold short. Based on an average trading volume of 63,451 shares, the short-interest ratio is currently 2.5 days.

Shuttle Pharmaceuticals Stock Performance

SHPH opened at $1.42 on Thursday. The company has a fifty day moving average of $1.81 and a two-hundred day moving average of $3.04. Shuttle Pharmaceuticals has a fifty-two week low of $1.26 and a fifty-two week high of $25.25. The stock has a market capitalization of $2.27 million, a price-to-earnings ratio of -0.12 and a beta of -1.00.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its earnings results on Thursday, November 13th. The company reported ($1.05) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, November 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Shuttle Pharmaceuticals currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

A hedge fund recently bought a new stake in Shuttle Pharmaceuticals stock. Connective Capital Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned approximately 9.40% of Shuttle Pharmaceuticals at the end of the most recent quarter. 4.58% of the stock is currently owned by institutional investors and hedge funds.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .